吉非替尼治疗化疗耐药的中晚期非小细胞肺癌42例

Forty-two Patients with Advanced Non-small Cell Lung Cancer Were Treated with Gifitinib

目的观察吉非替尼治疗化疗耐药的中、晚期非小细胞肺癌的疗效和不良反应。方法对经病理确诊的中、晚期非小细胞肺癌,经多程化疗后无效或不能耐受放化疗的患者给予吉非替尼250mg,口服,每日1次,至病情进展为止,观察吉非替尼的疗效和不良反应以及患者的生存期和疾病进展时间。结果42例患者,CR1例,PR13例,SD16例,PD12例,总缓解率33.33%,疾病控制率71.43%,中位疾病进展时间6.0个月,中位生存期9.2个月,吉非替尼的主要不良反应有皮疹、皮肤瘙痒、腹泻。结论吉非替尼单药治疗化疗耐药的中、晚期非小细胞肺癌安全、有效,毒副反应可耐受,可作为多程治疗后疗效欠佳或不能耐受放化疗患者的选择。

Objective To investigate the antitumor effects and adverse reactions of gefitinib in treating advanced non-small cell lung cancer. Methods Forty-two patients who were right pathologically diagnosed with advanced non-small cell lung cancer and failed prior chemotherapy and radiotherapy were administered orally with gefitinib 250 mg, once a day until cancer progressed or severe toxicity occurred. The efficacy adverse reactions of gefitinib survival and disease progression time of patients were observed. Results Among the 42 patients, 1 cases got complete response （CR）, 13 partial response（PR）, 16 stable disease（SD） and 12 progression disease（PD）. The total response rate was 33.33% and the disease control rate was 71.43%. The median time to progression was 6.0 months and the median survival time was 9. 2 months. The major adverse reactions of gefitinib included rash, itching and diarrhea. Conclusion Gefitinib was effective and safe for patients with advanced non-small cell lung cancer who failed prior chemotherapy and radiotherapy. The toxicities of gefitinib were tolerable. Gefitinib is a good choice for the patients with advanced non-small cell lung cancer who were resistant to chemotherapy and radiotherapy.